Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK). The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx
Read MoreCancer treatment is slowly shifting away from the standard chemo and radiation and more towards immunotherapy as an alternative treatment. Unlike chemotherapy which destroys healthy, rapidly dividing cells in the body, immunotherapy is more targeted, using the patient’s own immune system to fight cancer. Chemotherapy’s attack on healthy cells causes the well known side effects
Read MoreDespite the many advances in cancer therapy, we still haven’t quite hit the nail on the head, with cancer still responsible for 12% of all deaths worldwide each year. The advancement of cancer therapies and the growing body of research is impressive to say the least, yet cancer patients of today do not fare much
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.